|
Sorrento Therapeutics, Inc. (SRNE) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Sorrento Therapeutics, Inc. (SRNE) Bundle
Whether you’re an investor or analyst, this (SRNE) DCF Calculator is your go-to resource for accurate valuation. Preloaded with real data from Sorrento Therapeutics, Inc., you can adjust forecasts and instantly observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.2 | 31.4 | 40.0 | 52.9 | 62.8 | 82.7 | 108.9 | 143.4 | 188.8 | 248.5 |
| Revenue Growth, % | 0 | 48.31 | 27.21 | 32.31 | 18.78 | 31.65 | 31.65 | 31.65 | 31.65 | 31.65 |
| EBITDA | -147.1 | -308.4 | -275.7 | -436.0 | -539.9 | -82.7 | -108.9 | -143.4 | -188.8 | -248.5 |
| EBITDA, % | -694.08 | -981.15 | -689.47 | -824.11 | -859.22 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 9.1 | 15.0 | 14.7 | 16.3 | 13.2 | 29.7 | 39.1 | 51.4 | 67.7 | 89.1 |
| Depreciation, % | 42.72 | 47.86 | 36.79 | 30.84 | 21.08 | 35.86 | 35.86 | 35.86 | 35.86 | 35.86 |
| EBIT | -156.2 | -323.4 | -290.4 | -452.3 | -553.2 | -82.7 | -108.9 | -143.4 | -188.8 | -248.5 |
| EBIT, % | -736.8 | -1029.01 | -726.25 | -854.95 | -880.3 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 168.6 | 22.5 | 56.5 | 126.9 | 50.0 | 74.7 | 98.3 | 129.4 | 170.3 | 224.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.4 | 14.5 | 15.5 | 18.7 | 24.5 | 29.7 | 39.1 | 51.5 | 67.8 | 89.3 |
| Account Receivables, % | 20.57 | 45.98 | 38.78 | 35.38 | 38.94 | 35.93 | 35.93 | 35.93 | 35.93 | 35.93 |
| Inventories | .0 | 3.4 | 1.8 | 8.1 | 10.0 | 7.7 | 10.1 | 13.3 | 17.5 | 23.1 |
| Inventories, % | 0 | 10.7 | 4.58 | 15.32 | 15.88 | 9.29 | 9.29 | 9.29 | 9.29 | 9.29 |
| Accounts Payable | 13.8 | 27.6 | 24.7 | 27.4 | 47.5 | 56.6 | 74.6 | 98.2 | 129.2 | 170.2 |
| Accounts Payable, % | 65.2 | 87.9 | 61.79 | 51.82 | 75.61 | 68.46 | 68.46 | 68.46 | 68.46 | 68.46 |
| Capital Expenditure | -21.2 | -11.4 | -37.6 | -8.9 | -13.7 | -44.5 | -58.6 | -77.1 | -101.5 | -133.7 |
| Capital Expenditure, % | -100.01 | -36.4 | -93.98 | -16.77 | -21.73 | -53.78 | -53.78 | -53.78 | -53.78 | -53.78 |
| Tax Rate, % | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 |
| EBITAT | -148.7 | -323.0 | -288.5 | -419.5 | -564.1 | -80.6 | -106.1 | -139.7 | -183.9 | -242.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -151.4 | -319.1 | -313.8 | -418.9 | -552.0 | -89.3 | -119.6 | -157.4 | -207.2 | -272.8 |
| WACC, % | 6.08 | 6.37 | 6.34 | 5.92 | 6.38 | 6.22 | 6.22 | 6.22 | 6.22 | 6.22 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -685.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -278 | |||||||||
| Terminal Value | -6,594 | |||||||||
| Present Terminal Value | -4,877 | |||||||||
| Enterprise Value | -5,562 | |||||||||
| Net Debt | 111 | |||||||||
| Equity Value | -5,673 | |||||||||
| Diluted Shares Outstanding, MM | 419 | |||||||||
| Equity Value Per Share | -13.53 |
What You Will Get
- Real SRNE Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess Sorrento’s future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Data: Sorrento Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe Sorrento Therapeutics’ intrinsic value recalculating instantly.
- Visual Performance Metrics: Interactive dashboard charts showcase valuation results and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-built Excel file containing Sorrento Therapeutics, Inc. (SRNE) financial data.
- Customize: Tailor forecasts, including revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and evaluate results immediately.
- Make Decisions: Leverage the valuation outcomes to inform your investment choices.
Why Choose Sorrento Therapeutics (SRNE)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Expertise: A team of seasoned professionals dedicated to advancing biotechnology.
- Robust Pipeline: A diverse range of products in various stages of development.
- Commitment to Quality: Stringent processes ensure the highest standards in research and development.
- Collaborative Approach: Partnerships with leading organizations to enhance therapeutic outcomes.
Who Should Use This Product?
- Biotechnology Students: Explore drug development processes and analyze real-world data.
- Researchers: Utilize advanced models to enhance studies in pharmaceutical innovation.
- Investors: Evaluate your investment strategies and assess valuation metrics for Sorrento Therapeutics, Inc. (SRNE).
- Market Analysts: Optimize your analysis with a tailored DCF model specific to biotech companies.
- Healthcare Entrepreneurs: Understand how major biotech firms like Sorrento Therapeutics are valued and analyzed.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Sorrento Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models displaying intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Sorrento Therapeutics, Inc. (SRNE).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to facilitate easy analysis of results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.